Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone γ-H2AX asa biomarker of DNA damage

Cancer Research

Volumn 67, Issue 20, 2007, Pages 9971-9979

  Rao, V Ashutosh ^a   Agama, Keli ^a   Holbeck, Susan ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATRACYLIN; CAMPTOTHECIN; CHECKPOINT KINASE 2; DEOXYRIBONUCLEOPROTEIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; HISTONE GAMMA H2AX; HISTONE H2AX; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA CLEAVAGE; DNA DAMAGE; DNA DETERMINATION; DNA STRAND BREAKAGE; DRUG ACTIVITY; DRUG HALF LIFE; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA BREAKS, SINGLE-STRANDED; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; HCT116 CELLS; HISTONES; HT29 CELLS; HUMANS; PHOSPHORYLATION; QUINAZOLINES; TUMOR MARKERS, BIOLOGICAL;

EID: 35448964674     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0804     Document Type: Article

References (50)

1. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev 2002;3:430-40.
2. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
3. Pommier Y, Redon C, Rao VA, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 2003;532:173-203.
4. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361:2235-42.
5. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anti-Canc Agents 2005;5:363-72.
6. Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003;22:7296-304.
7. Pommier Y, Leteurtre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994;12:530-42.
8. Mucci-LoRusso P, Polin L, Bissery MC, et al. Activity of batracylin (NSC-320846) against solid tumors of mice. Invest New Drugs 1989;7:295-306.
9. Plowman J, Paull KD, Atassi G, et al. Preclinical antitumor activity of batracylin (NSC 320846). Invest New Drugs 1988;6:147-53.
10. Atassi G, Dumont P, Kabbe HJ, Yoder O. A new antitumour agent, batracylin, selected by a preclinical solid tumour model. Drugs Exp Clin Res 1988;14:571-4.
11. Luo Y, Ren YF, Chou TC, et al. A structure-activity relationship study of batracylin analogues. Pharm Res 1993;10:918-23.
12. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
13. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66.
14. Moreau P, Holbeck S, Prudhomme M, Sausville EA. Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines. Anticancer Drugs 2005;16:145-50.
15. Sedelnikova OA, Bonner WM. γH2AX in Cancer Cells: A Potential Biomarker for Cancer Diagnostics, Prediction and Recurrence. Cell Cycle 2006;5:2909-13.
16. Rao VA, Fan AM, Meng L, et al. Phosphorylation of BLM, dissociation from topoisomerase IIIα, and colocalization with γ-H2AX after topoisomerase I-induced replication damage. Mol Cell Biol 2005;25:8925-37.
17. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003;63:4347-50.
18. Bassing CH, Alt FW. H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity. Cell Cycle 2004;3:149-53.
19. Furuta T, Takemura H, Liao ZY, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003;278:20303-12.
20. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev 2003;3:155-68.
21. Takemura H, Rao VA, Sordet O, et al. Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J Biol Chem 2006;281:30814-23.
22. Antony S, Agama KK, Miao ZH, et al. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c ]isoquinoline)-6-propylamino} propane bis(-trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol Pharmacol 2006;70:1109-20.
23. Kohn KW. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 1996;18:505-13.
24. Kohn KW. Principles and practice of DNA filter elution. Pharmacol Ther 1991;49:55-77.
25. Pommier Y, Schwartz RE, Kohn KW, Zwelling LA. Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents. Biochemistry 1984;23:3194-201.
26. Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv Cancer Res 2001;80:189-216.
27. Miao ZH, Rao VA, Agama K, Antony S, Kohn KW, Pommier Y. 4-nitroquinoline-1-oxide induces the formation of cellular topoisomerase I-DNA cleavage complexes. Cancer Res 2006;66:6540-5.
28. Sinha BK, Haim N, Dusre L, Kerrigan D, Pommier Y. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res 1988;48:5096-100.
29. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-506.
30. Pommier Y, Sordet O, Rao VA, Zhang H, Kohn KW. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des 2005;11:2855-72.
31. Melchionna R, Chen XB, Blasina A, McGowan CH. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol 2000;2:762-5.
32. Etievant C, Kruczynski A, Barret JM, et al. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemother Pharmacol 2000;46:101-13.
33. Leteurtre F, Fujimori A, Tanizawa A, et al. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J Biol Chem 1994;269:28702-7.
34. Denny WA. Dual topoisomerase I/II poisons as anticancer drugs. Expert Opin Investig Drugs 1997;6:1845-51.
35. Finlay GJ, Riou JF, Baguley BC. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 1996;32A:708-14.
36. Ishida K, Asao T. Self-association and unique DNA binding properties of the anti-cancer agent TAS-103, a dual inhibitor of topoisomerases I and II. Biochim Biophys Acta 2002;1587:155-63.
37. Larsen AK, Grondard L, Couprie J, et al. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol 1993;46:1403-12.
38. Adjei AA, Charron M, Rowinsky EK, et al. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res 1998;4:683-91.
39. Demarquay D, Coulomb H, Huchet M, et al. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor. Ann N Y Acad Sci 2000;922:301-2.
40. Spicer JA, Gamage SA, Rewcastle GW, et al. Bis(phenazine-1-carboxamides): structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs. J Med Chem 2000;43:1350-8.
41. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989;49:5016-22.
42. Vicker N, Burgess L, Chuckowree IS, et al. Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. J Med Chem 2002;45:721-39.
43. Denny WA. Emerging DNA topisomerase inhibitors as anticancer drugs. Expert Opin Emerg Drugs 2004;9:105-33.
44. Nakamura A, Sedelnikova OA, Redon C, et al. Techniques for γ-H2AX detection. Methods Enzymol 2006;409:236-50.
45. Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM. Characteristics of γ-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol 2003;81:123-9.
46. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quantitative detection of (125)IdU-induced DNA double-strand breaks with γ-H2AX antibody. Radiat Res 2002;158:486-92.
47. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.
48. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: the histone guardian of the genome. DNA Repair 2004;3:959-67.
49. Kao J, Milano MT, Javaheri A, et al. γ-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets 2006;6:197-205.
50. Lobrich M, Rief N, Kuhne M, et al. In vivo formation and repair of DNA double-strand breaks after computed tomography examinations. Proc Natl Acad Sci U S A 2005;102:8984-9.